Work on the mobile diagnostic platform – Genomtec ID, began in 2017 and currently we are starting its industrialization, proudly presenting its final prototype version. The company’s flagship project utilizes the proprietary, patented SNAAT® isothermal technology and comprises of a device and a microfluidic reaction card. The mobility of the Genomtec ID platform is ensured by its small size – the entire IVD device fits onto one hand, while the patented SNAAT® technology, based on the verified LAMP isothermal amplification (synthesis) of the genetic material, allows for genetic testing even in 15 minutes. Ultimately, the Genomtec ID system will be used at Point-Of-Care diagnostic testing (POCT), e.g. at doctor’s offices, during home visits or by the ambulance services, and among others will diagnose respiratory tract infections, including the diagnosis of COVID-19 disease caused by SARS-CoV-2 virus. The industrialisation and production process will be conducted in close cooperation with an international CMO (Contract Manufacturing Organization) company. The commercialization of the platform is planned for the first half of 2022.
